首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery.
【24h】

Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery.

机译:N-乙酰半胱氨酸预防大手术后急性肾功能衰竭的荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Acute renal failure after major surgery is associated with significant mortality and morbidity that theoretically may be attenuated by N-acetylcysteine. DESIGN: Meta-analysis of relevant studies sourced from the Cochrane Controlled Trial Register (2007 issue 4), EMBASE, and MEDLINE databases (1966 to February 1, 2008) without language restriction. SETTING & POPULATION: Adult patients undergoing major surgery without the use of radiocontrast. SELECTION CRITERIA FOR STUDIES: Randomized controlled studies comparing N-acetylcysteine with a placebo perioperatively. DATA ANALYSIS: Categorical variables are reported as odds ratio (OR) with 95% confidence interval (CI), and continuous variables are reported as weighted-mean-difference (WMD) with 95% CI. OUTCOME MEASURES: Effects of N-acetylcysteine on mortality and acute renal failure requiring dialysis were the main outcomes of interest. Additional outcome measures included an incremental increase in serum creatinine concentration greater than 25%above baseline, surgical reexploration for bleeding, amount of allogeneic blood transfusion, and length of intensive care unit stay. RESULTS: 10 studies involving a total of 1,193 adult patients undergoing major surgery were considered. N-Acetylcysteine use was not associated with a decrease in mortality (OR, 1.05; 95% CI, 0.58 to 1.92), acute renal failure requiring dialysis (OR, 1.04; 95% CI, 0.45 to 2.37), incremental increase in serum creatinine concentration greater than 25% above baseline (OR, 0.84; 95% CI, 0.64 to 1.11), or length of intensive care unit stay (WMD in days, 0.46; 95% CI, -0.43 to 1.36). N-acetylcysteine did not appear to increase the risk of surgical reexploration for bleeding (OR, 1.16; 95% CI, 0.57 to 2.38) or amount of allogeneic blood transfusion required (WMD in units, 0.31; 95% CI, -0.21 to 0.84). LIMITATIONS: Most studied patients had cardiac surgery and normal renal function preoperatively. CONCLUSIONS: There is no current evidence that N-acetylcysteine used perioperatively can alter mortality or renal outcomes when radiocontrast is not used.
机译:背景:大手术后的急性肾衰竭与显着的死亡率和发病率相关,理论上可以通过N-乙酰半胱氨酸减轻。设计:对相关研究的荟萃分析来自Cochrane对照试验注册簿(2007年第4期),EMBASE和MEDLINE数据库(1966年至2008年2月1日),没有语言限制。地点和人口:成年患者在不进行放射线造影的情况下进行了大手术。研究的选择标准:围手术期比较N-乙酰半胱氨酸与安慰剂的随机对照研究。数据分析:分类变量报告为具有95%置信区间(CI)的比值比(OR),连续变量报告为具有95%CI的加权均值差(WMD)。观察指标:N-乙酰半胱氨酸对死亡率和需要透析的急性肾功能衰竭的影响是主要的研究结果。额外的结局指标包括:血清肌酐浓度高于基线水平增加25%以上,手术探查出血,异体输血量以及重症监护病房住院时间。结果:10项研究共涉及1193名接受大手术的成年患者。使用N-乙酰半胱氨酸与死亡率降低(OR,1.05; 95%CI,0.58至1.92),需要透析的急性肾衰竭(OR,1.04; 95%CI,0.45至2.37),血清肌酐水平的增加无关。浓度高于基线以上25%(OR,0.84; 95%CI,0.64至1.11)或重症监护病房住院时间(WMD以天为单位,0.46; 95%CI,-0.43至1.36)。 N-乙酰半胱氨酸似乎不增加出血的手术再手术风险(OR,1.16; 95%CI,0.57至2.38)或所需的异体输血量(WMD,0.31; 95%CI,-0.21至0.84) )。局限性:大多数研究患者术前进行心脏手术且肾功能正常。结论:目前尚无证据表明围手术期使用N-乙酰半胱氨酸不使用放射线造影剂可改变死亡率或肾脏预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号